Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue

APMIS

Volumn 118, Issue 5, 2010, Pages 360-365

  Valdman, Alexander ^a   Jaraj, Sara Jonmarker ^a   Compérat, Eva ^b   Charlotte, Fréderic ^b   Roupret, Morgan ^b   Pisa, Pavel ^a   Egevad, Lars ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Foxp3; Immunohistochemistry; Prostate; Prostate cancer; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; ATROPHY; BENIGN TUMOR; CARCINOGENESIS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; LYMPHOID PROGENITOR CELL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; TISSUE MICROARRAY;

AGED; ATROPHY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; T-LYMPHOCYTES, REGULATORY;

EID: 77951104539     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2010.02604.x     Document Type: Article

References (28)

1. Baade P, Youlden D, Krnjacki L. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009 53 : 171 184.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005 55 : 10 30.
3. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007 7 : 256 269.
4. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25 regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001 182 : 18 32.
5. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995 155 : 1151 1164.
6. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004 10 : 801 805.
7. Chen ML, Pittet M, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-OI signals in vivo. Proc Natl Acad Sci U S A 2005 102 : 419 424.
8. + helper T cell responses in cancer patients. Blood 2005 106 : 1008 1011.
9. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007 117 : 1167 1174.
10. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003 299 : 1057 1061.
11. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002 16 : 311 323.
12. + effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med 2003 197 : 181 193.
13. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005 23 : 515 548.
14. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. Regulatory T cells in patients with gastrointestinal malignancies. Cancer 2003 98 : 1089 1099.
15. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004 173 : 1444 1453.
16. Kawaida H, Kono K, Takahashi A, Sugai H, Mimura K, Miyagawa N, et al. Distribution of CD4(+)CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 2005 124 : 151 157.
17. high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006 177 : 7398 7405.
18. + regulatory T Treg cells in prostate carcinoma. Anal Quant Cytol Histol 2009 in press.
19. Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 2003 27 : 1291 1301.
20. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007 177 : 540 545.
21. Ziegler S. FOXP3: not just for regulatory T cells anymore. Eur J Immunol 2007 37 : 21 3.
22. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999 155 : 1985 1992.
23. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005 26 : 1170 1181.
24. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000 56 : 828 832.
25. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006 12 : 6808 6816.
26. + regulatory T cell compartment. J Immunol 2004 173 : 2227 2230.
27. + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009 27 : 186 192.
28. + regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008 14 : 1032 1040.